Muscular Dystrophy

This practical and concise guide offers an overview of muscular dystrophy's complicated features, treatment options and general resources. New treatments and a greater understanding of proteins and structures associated with MD are discussed along with long term patient care. Also included are clinical and developmental challenges within the current regulatory landscape and recent scientific and clinical advances. Muscular Dystrophy offers clinicians, researchers, pharmaceutical executives and patient advocacy groups an easy-to-read reference that provides the necessary perspectives of the care giver and patient.

• Early Stage Products, late stage products
• Global and National Patient Registries
• Mobility Assisted Devices, Patient Advocacy Groups
• Muscular Dystrophy, Duchenne and Becker
• Regulatory Guidance, Physical Therapy
• pharmacotherapy

• Biosimilars Center of Excellence, Quintiles, Inc., Durham, USA

  Raymond A. Huml

Raymond A. Huml, MS, DVM, RAC, is Executive Director, Strategic Drug Development, in the Biosimilars Center of Excellence at Quintiles. He was recently the author of the SpringerBrief, Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional. He has recruited several prominent MD's to contribute chapters to Muscular Dystrophy: A Concise Guide.

Policies and ethics